Claire Mazumdar, Bicara Therapeutics CEO

Red Tree, RA Cap­i­tal lead $108M in­fu­sion in­to Bicara and its bi­func­tion­al I/O drug

Bicara Ther­a­peu­tics, the Bio­con spin­out work­ing on a new kind of im­munother­a­py, has bagged $108 mil­lion to push its lead can­di­date deep­er in­to the clin­ic.

Its top pro­gram, BCA101, hits two fa­mil­iar tar­gets in the can­cer space, EGFR and TGF-β. What Bicara aims to do, though, is cre­ate a bi­func­tion­al an­ti­body that si­mul­ta­ne­ous­ly blocks EGFR and us­es that as a hom­ing mech­a­nism to trap TGF-β, a cy­tokine that pro­motes can­cer growth, at the tu­mor site.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.